Ghent University Academic Bibliography

Advanced

Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults

Geert Leroux-Roels UGent, Pierre Van Damme, Wouter Haazen, Sepehr Shakib, Magalie Caubet, Emmanuel Aris, Jeanne-Marie Devaster and Mathieu Peeters (2016) VACCINE. 34(27). p.3156-3163
abstract
Background: Non-typeable Haemophilus influenzae (NTHi) is a major cause of various respiratory diseases. The development of an effective vaccine against NTHi mandates new approaches beyond conjugated vaccines as this opportunistic bacterium is non-encapsulated. Here we report on the safety, reactogenicity and immunogenicity of a multi-component investigational vaccine based on three conserved surface proteins from NTHi (proteins D [PD],E [PE] and Pilin A [PilA]) in two observer-blind phase I studies. Methods: In the first study (NCT01657526), 48 healthy 18-40 year-olds received two vaccine formulations (10 or 30 mu g of each antigen [PD and a fusion protein PE-PilA]) or saline placebo at months 0 and 2. In the second study (NCT01678677), 270 50-70 year-olds, current or former smokers, received eight vaccine formulations (10 or 30 mu g antigen/dose non-adjuvanted or adjuvanted with alum, AS01(E) or ASO4(c)) or saline placebo at months 0,2 and 6 (plain and alum-adjuvanted groups) and at months 0 and 2 (AS-adjuvanted groups). Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days post-vaccination, respectively; potential immune-mediated diseases (pIMDs) and serious AEs (SAEs) throughout the studies. Humoral and antigen-specific T-cell immunity (in study 2 only) responses were assessed up to 12 months post-vaccination. Results: Observed reactogenicity was highest in the AS-adjuvanted groups but no safety concerns were identified with any of the NTHi vaccine formulations. One fatal SAE (cardiac arrest) not considered related to vaccination, and one pIMD (non-serious psoriasis) in the Placebo group, were reported post-dose 3 in Study 2. All formulations generated a robust antibody response while the AS01-adjuvanted formulations produced the highest humoral and cellular immune responses. Conclusion: This study confirms that the NTHi vaccine formulations had an acceptable reactogenicity and safety profile and were immunogenic in adults. These results justify further clinical development of this NTHi vaccine candidate.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
NTHi, Safety, Immunogenicity, Adjuvant, Adult vaccination, OBSTRUCTIVE PULMONARY-DISEASE, STREPTOCOCCUS-PNEUMONIAE, ADJUVANT SYSTEMS, IMMUNITY, PREVENTION, RESISTANCE, PATHOGEN, EFFICACY, ANTIBODY, ADHESIN
journal title
VACCINE
Vaccine
volume
34
issue
27
pages
3156 - 3163
Web of Science type
Article
Web of Science id
000378667900022
JCR category
MEDICINE, RESEARCH & EXPERIMENTAL
JCR impact factor
3.235 (2016)
JCR rank
38/128 (2016)
JCR quartile
2 (2016)
ISSN
0264-410X
DOI
10.1016/j.vaccine.2016.04.051
language
English
UGent publication?
yes
classification
A1
copyright statement
Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)
id
8528403
handle
http://hdl.handle.net/1854/LU-8528403
date created
2017-08-08 08:01:45
date last changed
2017-10-19 08:14:44
@article{8528403,
  abstract     = {Background: Non-typeable Haemophilus influenzae (NTHi) is a major cause of various respiratory diseases. The development of an effective vaccine against NTHi mandates new approaches beyond conjugated vaccines as this opportunistic bacterium is non-encapsulated. Here we report on the safety, reactogenicity and immunogenicity of a multi-component investigational vaccine based on three conserved surface proteins from NTHi (proteins D [PD],E [PE] and Pilin A [PilA]) in two observer-blind phase I studies. 
Methods: In the first study (NCT01657526), 48 healthy 18-40 year-olds received two vaccine formulations (10 or 30 mu g of each antigen [PD and a fusion protein PE-PilA]) or saline placebo at months 0 and 2. In the second study (NCT01678677), 270 50-70 year-olds, current or former smokers, received eight vaccine formulations (10 or 30 mu g antigen/dose non-adjuvanted or adjuvanted with alum, AS01(E) or ASO4(c)) or saline placebo at months 0,2 and 6 (plain and alum-adjuvanted groups) and at months 0 and 2 (AS-adjuvanted groups). Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days post-vaccination, respectively; potential immune-mediated diseases (pIMDs) and serious AEs (SAEs) throughout the studies. Humoral and antigen-specific T-cell immunity (in study 2 only) responses were assessed up to 12 months post-vaccination. 
Results: Observed reactogenicity was highest in the AS-adjuvanted groups but no safety concerns were identified with any of the NTHi vaccine formulations. One fatal SAE (cardiac arrest) not considered related to vaccination, and one pIMD (non-serious psoriasis) in the Placebo group, were reported post-dose 3 in Study 2. All formulations generated a robust antibody response while the AS01-adjuvanted formulations produced the highest humoral and cellular immune responses. 
Conclusion: This study confirms that the NTHi vaccine formulations had an acceptable reactogenicity and safety profile and were immunogenic in adults. These results justify further clinical development of this NTHi vaccine candidate.},
  author       = {Leroux-Roels, Geert and Van Damme, Pierre and Haazen, Wouter and Shakib, Sepehr and Caubet, Magalie and Aris, Emmanuel and Devaster, Jeanne-Marie and Peeters, Mathieu},
  issn         = {0264-410X},
  journal      = {VACCINE},
  keyword      = {NTHi,Safety,Immunogenicity,Adjuvant,Adult vaccination,OBSTRUCTIVE PULMONARY-DISEASE,STREPTOCOCCUS-PNEUMONIAE,ADJUVANT SYSTEMS,IMMUNITY,PREVENTION,RESISTANCE,PATHOGEN,EFFICACY,ANTIBODY,ADHESIN},
  language     = {eng},
  number       = {27},
  pages        = {3156--3163},
  title        = {Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults},
  url          = {http://dx.doi.org/10.1016/j.vaccine.2016.04.051},
  volume       = {34},
  year         = {2016},
}

Chicago
Leroux-Roels, Geert, Pierre Van Damme, Wouter Haazen, Sepehr Shakib, Magalie Caubet, Emmanuel Aris, Jeanne-Marie Devaster, and Mathieu Peeters. 2016. “Phase I, Randomized, Observer-blind, Placebo-controlled Studies to Evaluate the Safety, Reactogenicity and Immunogenicity of an Investigational Non-typeable Haemophilus Influenzae (NTHi) Protein Vaccine in Adults.” Vaccine 34 (27): 3156–3163.
APA
Leroux-Roels, G., Van Damme, P., Haazen, W., Shakib, S., Caubet, M., Aris, E., Devaster, J.-M., et al. (2016). Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. VACCINE, 34(27), 3156–3163.
Vancouver
1.
Leroux-Roels G, Van Damme P, Haazen W, Shakib S, Caubet M, Aris E, et al. Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults. VACCINE. 2016;34(27):3156–63.
MLA
Leroux-Roels, Geert, Pierre Van Damme, Wouter Haazen, et al. “Phase I, Randomized, Observer-blind, Placebo-controlled Studies to Evaluate the Safety, Reactogenicity and Immunogenicity of an Investigational Non-typeable Haemophilus Influenzae (NTHi) Protein Vaccine in Adults.” VACCINE 34.27 (2016): 3156–3163. Print.